主题：人多能间充质干细胞在不表达IFNγR1信号和IDO前提下抑制PBMCs增殖# M! i9 |) h; H% E* j7 r t3 `
/ S6 G9 r( U2 s1 K0 L 说明：原文来自Blood，干细胞之家新闻小组成员deron翻译（转帖请注明） 2 f' u( Z+ Y' H + D9 A3 ]" D. L翻译内容：# ^, n0 p r# L/ ]: D$ D. K- Y
多能间充质干细胞（MSCs）抑制体外大多数（如果不是全部的话）外周血单核细胞（PBMC）亚群的增殖、辅助和效应功能。研究者广泛认为这种抑制效应的分子机制涉及干扰素γ（IFNγ）诱导的吲哚胺2，3加双氧酶（IDO）表达。然而，IDO抑制剂不能恢复所有（抑制反应）条件下PBMCs的增殖。更重要的是，IFNγ受体1（R1）缺失的人MSCs与对照组MSCs相比，抑制HLA错配PBMCs的程度接近。与健康MSCs相比，无论IFNγ存在与否，抑或是与HLA错配的PBMCs共培养，我们在IFNγR1缺乏的MSCs中未发现可检测程度的IDO mRNA。基于基因表达谱，我们能够证明胰岛素样生长因子（IGF）结合蛋白参与MSCs的抑制机制。综上所述，人MSCs在无IFNγR1信号和IDO的前提下可以发挥重要的免疫调节功能，这种现象部分是由IGF结合蛋白参与引起。5 e8 _$ j5 Z+ _! I% g/ Z1 l
原摘要：Multipotent mesenchymal stromal cells (MSCs) inhibit proliferation, helper, and effector functions in most if not all peripheral blood mononuclear cell (PBMC) subpopulations in vitro. The molecular mechanism is widely thought to imply tryptophan degradation by the interferon-gamma (IFNgamma)-induced expression of indoleamine 2,3-dioxygenase (IDO). However, IDO inhibitors were not able to restore proliferation of PBMCs in each case. Moreover, human MSCs with an IFNgamma receptor 1 (R1) defect inhibited proliferation of HLA-mismatched PBMCs to a similar extent as control MSCs. In contrast to healthy MSCs, IFNgammaR1-deficient MSCs showed no detectable mRNA for IDO-neither in the absence nor in the presence of recombinant human IFNgamma, nor in coculture with HLA-mismatched PBMCs. Based on gene expression profiling, we were able to show that insulin-like growth factor (IGF)-binding proteins contribute to the inhibitory mechanism of MSCs. Taken together, human MSCs exert important immunomodulatory functions in the absence of IFNgammaR1 signaling and IDO, partially accounted for by IGF-binding proteins.7 J( L! x& v/ ~5 h% [7 Y& q7 U# W8 B
0 q, y9 J9 V2 Q- ?: Y8 H"proliferation, helper, and effector functions"或许翻译为“增殖、辅助者和效应物功能”更好一些。 * m' I8 w/ ~ [8 |4 l/ P % i% d, k! D$ j; a indoleamine 2,3-dioxygenase (IDO)应译为“吲哚胺2,3双加氧酶(IDO)”。9 b. F2 Y/ s" `' ~! h2 C- Q
! M) F0 x% Y( j" The molecular mechanism is widely thought to imply tryptophan degradation by the interferon-gamma (IFNgamma)-induced expression of indoleamine 2,3-dioxygenase (IDO)"中楼主翻译为“研究者广泛认为这种抑制效应的分子机制涉及干扰素γ（IFNγ）诱导的吲哚胺2,3加双氧酶（IDO）表达”似乎遗漏了“tryptophan degradation”的意思，不妥。imply是指“暗示，提示”的意思。这里尝试译作“研究者广泛认为这种分子机制涉及干扰素γ（IFNγ）诱导表达的吲哚胺2,3双加氧酶（IDO）降解色氨酸”。作者: naturalkillerce 时间: 2011-9-25 09:30
回复 deron 的帖子 / ^4 g- @: l/ Z2 j / j: }- p( c) i8 `+ [( f9 }# ^ “IFNgamma receptor 1 (R1) defect ”中的defect应该翻译为“缺陷”而不是deficient(缺损的、缺乏的)，试译为“IFNγ受体1（R1）存在缺陷”。 / J0 s. T4 P8 j 4 ~+ m+ ~. ]1 N2 @# Q“ Moreover, human MSCs with an IFNgamma receptor 1 (R1) defect inhibited proliferation of HLA-mismatched PBMCs to a similar extent as control MSCs”应译为“与对照组MSCs相比，IFNγ受体1（R1）存在缺陷的人MSCs同样程度地抑制HLA错配的PBMCs增殖”。即应是“抑制HLA错配PBMCs增殖程度”。! K. l" y7 G3 N' X5 y
! p: \8 k( U ^+ i T“---IDO-neither in the absence nor in the presence of recombinant human IFNgamma, nor in coculture with HLA-mismatched PBMCs”应该译为“在没有自然状态下IFNγ缺失，也没有重组性人IFNγ存在情形(注：楼主遗漏了“重组”这个单词的翻译)下，也在没有与HLA错配的PBMCs共培养情形下”或许更好。作者: deron 时间: 2011-9-25 10:12